Study of the Plasma and Buffy Coat in Patients with SARS-CoV-2 Infection—A Preliminary Report
Karla B. Peña,
Francesc Riu,
Josep Gumà,
Carmen Guilarte,
Berta Pique,
Anna Hernandez,
Alba Àvila,
Sandra Parra,
Antoni Castro,
Conxita Rovira,
Pitter Cueto,
Immaculada Vallverdu,
David Parada
Affiliations
Karla B. Peña
Pathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Francesc Riu
Pathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Josep Gumà
Department of Oncology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Carmen Guilarte
Pathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Berta Pique
Pathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Anna Hernandez
Pathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Alba Àvila
Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Sandra Parra
Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Antoni Castro
Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Conxita Rovira
Department of Intensive Care Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Pitter Cueto
Department of Intensive Care Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
Immaculada Vallverdu
Department of Intensive Care Medicine, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
David Parada
Pathology Molecular Unit, Department of Pathology, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Facultat de Medicina, Universitat Rovira i Virgili, 43204 Reus, Spain
The pandemic caused by the SARS-CoV-2 infection affects many aspects of public health knowledge, science, and practice around the world. Several studies have shown that SARS-CoV-2 RNA in plasma seems to be associated with a worse prognosis of COVID-19. In the present study, we investigated plasma and buffy RNA in patients with COVID-19 to determine its prognostic value. A prospective study was carried out in patients hospitalized for COVID-19, in which RNA was analyzed in plasma and the buffy coat. Morphological and immunohistochemical studies were used to detect the presence of SARS-CoV-2 in the buffy coat. In COVID-19 patients, the obtained RNA concentration in plasma was 448.3 ± 31.30 ng/mL. Of all the patients with positive plasma tests for SARS-CoV-2, 46.15% died from COVID-19. In four cases, tests revealed that SARS-CoV-2 was present in the buffy coat. Abnormal morphology of monocytes, lymphocytes and neutrophils was found. An immunohistochemical study showed positivity in mononuclear cells and platelets. Our results suggest that SARS-CoV-2 is present in the plasma. This facilitates viral dissemination and migration to specific organs, where SARS-CoV-2 infects target cells by binding to their receptors. In our study, the presence of plasma SARS-CoV-2 RNA was correlated with worse prognoses.